Acarbose attenuates experimental non-alcoholic steatohepatitis
- 12 March 2004
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 315 (3), 699-703
- https://doi.org/10.1016/j.bbrc.2004.01.116
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Model of nonalcoholic steatohepatitisThe American Journal of Clinical Nutrition, 2004
- Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trialThe Lancet, 2002
- Nonalcoholic SteatohepatitisMayo Clinic Proceedings, 2000
- Metabolic and nutritional considerations in nonalcoholic fatty liverHepatology, 2000
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity☆, ☆☆Gastroenterology, 1999
- Altered Expression of HepaticCYP2E1andCYP4Ain Obese, Diabeticob/obMice, andfa/faZucker RatsBiochemical and Biophysical Research Communications, 1999
- Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importanceJournal of Hepatology, 1998
- Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammationGastroenterology, 1996
- Serum Procollagen Type III N‐Terminal Peptides and Laminin P1 Peptide in Alcoholic Liver DiseaseAlcohol: Clinical and Experimental Research, 1987
- Effect of drug administration on the activity of the hepatic microsomal ethanol oxidizing systemLife Sciences, 1970